Brolucizumab manufacturers
- Brolucizumab
-
- $3620.00
-
2026-07-27
- CAS:1531589-13-5
- Purity:
- Supply Ability: 10g
|
| | Brolucizumab Basic information |
| Product Name: | Brolucizumab | | Synonyms: | Brolucizumab;Research Grade Brolucizumab (DHD12603);Research Grade Brolucizumab;Brolucizumab (anti-VEGFA) | | CAS: | 1531589-13-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Brolucizumab Structure]() |
| | Brolucizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Brolucizumab Usage And Synthesis |
| Uses | Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2]. | | in vivo | Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) slows the growth of mSLK-KSHV xenograft tumors[2].
Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) delays in vivo tumor growth in U87MG glioma models[1].
Brolucizumab (10 mg/kg; i.v.) shows a half-life of 5.4-7.8 minutes for the rapid decline phase and 1.4-1.9 hours for the slow decline phase in mice[2]. | Animal Model: | NSG mice were subcutaneously injected with mSLK-KSHV cell suspension[2] | | Dosage: | 15 mg/kg | | Administration: | I.p. 5 days per week for 21 or 41 days | | Result: | Significantly lowed tumor growth there was no difference in survival between experimental and combined control groups.
|
| | References | [1] Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365(2):422-429. DOI:10.1124/jpet.117.246249
[2] Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15(5):e0233116. DOI:10.1371/journal.pone.0233116 |
| | Brolucizumab Preparation Products And Raw materials |
|